Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>Products>This Product
  Products


Boehringer Ingelheim RCV GmbH & Co KG

Product Description

Boehringer Ingelheim is one of the leading companies for development and manufacture of biopharmaceuticals by offering the entire production technology chain at its biopharmaceutical facilities in Biberach (Germany), in Fremont (USA) and in Vienna (Austria).

Among the world's top biopharmaceutical companies

All of the elements required for outsourcing biopharmaceutical development and manufacture, from high expression system to fill & finish, and patient convenient application systems can be found within the corporate capabilities of Boehringer Ingelheim in a so called One-Stop-Shop.
At our large-scale production sites in Vienna, Austria and Biberach, Germany we have extablished a strong track record in regulatory approval since more than 25 years. So far 19 DNA-derived biopharmaceutical products have been successfully introduced to the market.

A well-filled R&D pipeline

One of our major efforts is the development of new biological entities (NBEs) for the treatment of diseases in the areas of:

•    Respiratory
•    Cardiovascular
•    Virology
•    Neurology (CNS)
•    Immunology
•    Metabolism
•    Oncology

All R&D activities in these therapeutic areas are supported by Licensing for early and late stage pharmaceutical and biopharmaceutical products.

Product Boehringer Ingelheim RCV GmbH & Co KG
Company Boehringer Ingelheim
Price Request a quote
More Information View company product page
Catalog Number Unspecified
Quantity Unspecified
Company Logo

Boehringer Ingelheim
Binger Str. 173 Ingelheim am Rhein, 55216 Germany

Tel: +49-6132-770
Fax: +49-6132-720



Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
Investigating the Vape
Expert independent review concludes that e-cigarettes have potential to help smokers quit.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Researchers Discover Synthesis of a New Nanomaterial
Interdisciplinary team creates biocomposite for first time using physiological conditions.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Scroll Up
Scroll Down

Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!